Activity of ABT-773 against Mycobacterium avium Complex in the Beige Mouse Model
AUTOR(ES)
Cynamon, M. H.
FONTE
American Society for Microbiology
RESUMO
ABT-773, a new ketolide antimicrobial agent, was evaluated in comparison to clarithromycin (CLA) in vitro against Mycobacterium avium complex (MAC) and in a beige mouse model of disseminated MAC infection. The MICs at which 50 and 90% of the isolates tested were inhibited were 2 and 4 μg/ml, respectively, for CLA and 8 and 16 μg/ml, respectively, for ABT-773. Eight CLA-resistant isolates were found to be resistant to ABT-773 (MICs > 64 μg/ml). In the in vivo study mice were treated with ABT-773 (50, 100, and 200 mg/kg of body weight) or CLA (200 mg/kg). Both ABT-773 (100 and 200 mg/kg) and CLA significantly decreased the viable cell counts in spleens and lungs. ABT-773 (200 mg/kg) and CLA had similar activities in lungs, but the former was more active in spleens.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=90174Documentos Relacionados
- In Vivo Efficacy of the Ketolide ABT-773 (Cethromycin) against Enterococci in a Mouse Peritonitis Model
- In Vitro Activity of the Ketolide ABT-773
- Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model.
- Beige mouse model for Mycobacterium avium complex disease.
- Activities of ABT-773 against Microaerophilic and Fastidious Organisms